Released Sep 24, 2024, after the close
10-Q filed Sep 24, 2024, 86 days after period end · 0001683168-24-006623
Q2 2024 · 10-Q
Revenue—
Net Income-$6.57M-$6.57M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$4.20-$4.20 N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$5,435,449N/M
Operating Cash Flowderived-$2,673,638—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2024 | Q2 2023 |
|---|---|---|
| Net Income | -$6.57M | -$5.52M |
| EPS Diluted | -$4.20 | -$3.88 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR